Aimmune Therapeutics (NASDAQ: AIMT) gains 10% early following FDA briefing documents. An analyst at Baird called ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA Trader Talk

Piper Jaffray Sees Aimmune Therapeutics (AIMT) AR101 Approved Following Briefing DocsSeptember 11, 2019 10:15 AM FDA Posts Briefing Document for Aimmune Therapeutics' (AIMT) PalforziaSeptember 11, 2019 8:05 AM Aimmune Therapeutics (AIMT) Added to Fresh Pick List at BairdSeptember 9, 2019 7:36 AM